Compare MTDR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | BLTE |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | 2011 | 2021 |
| Metric | MTDR | BLTE |
|---|---|---|
| Price | $60.21 | $147.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 9 |
| Target Price | $69.71 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 1.2M | 133.0K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $3,696,277,000.00 | N/A |
| Revenue This Year | $16.02 | N/A |
| Revenue Next Year | $15.94 | N/A |
| P/E Ratio | $19.83 | ★ N/A |
| Revenue Growth | ★ 5.46 | N/A |
| 52 Week Low | $37.14 | $90.84 |
| 52 Week High | $66.84 | $200.00 |
| Indicator | MTDR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 39.67 |
| Support Level | $52.15 | $145.21 |
| Resistance Level | $60.38 | $161.08 |
| Average True Range (ATR) | 1.79 | 5.89 |
| MACD | 0.62 | -0.37 |
| Stochastic Oscillator | 91.81 | 30.70 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.